Related Experiment Videos
Treatment with recombinant human erythropoietin in children with malignancies
I Bolonaki1, E Stiakaki, E Lydaki
1Department of Pediatric Hematology-Oncology, University of Crete, Greece.
Insights
Recombinant human erythropoietin (rHuEPO) effectively treated anemia in pediatric cancer patients, reducing transfusion needs. Children with lower initial erythropoietin (EPO) levels responded best to rHuEPO therapy.
Area of Science:
- Pediatric Oncology
- Hematology
Background:
- Anemia is a common complication in children with cancer, impacting treatment tolerance and quality of life.
- Recombinant human erythropoietin (rHuEPO) is a therapeutic option to manage anemia.
Purpose of the Study:
- To evaluate the efficacy and safety of rHuEPO in treating anemia in pediatric cancer patients.
- To determine optimal dosing and identify predictors of response to rHuEPO therapy.
Main Methods:
- A study involving 15 children with hematologic malignancies or solid tumors experiencing anemia.
- rHuEPO administered at doses of 150, 250, or 400 IU/L for 8 weeks.
- Hemoglobin (Hb) and hematocrit (Hct) levels monitored; response defined as Hb > 10th percentile.
- Initial erythropoietin (EPO) levels measured to assess correlation with response.
Main Results:
- rHuEPO increased Hb and Hct in 46% of patients at 150 IU/L, with lower response rates at higher doses.
- Red blood cell transfusion requirements decreased by 66% post-treatment.
- No significant impact on leukocyte or platelet counts.
- Patients with initial EPO levels < 100 IU/L showed better response.
- rHuEPO was well-tolerated with no reported side effects.
Conclusions:
- rHuEPO is an effective and safe treatment for anemia in pediatric cancer patients.
- Lower baseline EPO levels predict a positive response to rHuEPO therapy.
- rHuEPO can reduce the need for blood transfusions in this population.
Abstract:
The effect of recombinant human erythropoietin (rHuEPO) on the anemia of cancer was examined in 15 children with hematologic malignancies (group I) and solid tumors (group II), whose hemoglobin (Hb) was under the third percentile for sex and age. The response to rHuEPO was defined as an increase of Hb to above the 10th percentile following 8 weeks of therapy. The rHuEPO caused an increase in the Hb and hematocrit (Hct) in 46% of children of both groups at a dose of 150 IU/L, in 28.5% of children at a dose of 250 IU/L and in 25.5% of children at a dose of 400 IU/L. Leukocyte and platelet counts were not influenced by the rHuEPO treatment. The red cell transfusion requirement decreased to 66% in both groups after rHuEPO treatment. Erythropoietin (EPO) levels were measured prior to the treatment and then every 4 weeks during rHuEPO treatment. Children who responded to EPO had an initial EPO level of < 100 IU/L, while those who did not respond had an initial EPO level of > 100 IU/L. Erythropoietin was well tolerated in all children, with no side effects.